Selected research
Industry Research
Neurometabolic Disorders Industry Research Report 2026
Market perspective
The global Neurometabolic Disorders market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Neurometabolic Disorders market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Neurometabolic Disorders market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Neurometabolic Disorders market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Neurometabolic Disorders include Amicus, Amicus Therapeutics, Biomarin, Biosidus, Dong-A Socio Group, ExSAR Corporation, Genzyme, Greencross and Greenovation Biotech, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Neurometabolic Disorders market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Neurometabolic Disorders.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Neurometabolic Disorders Market by Company
Amicus
Amicus Therapeutics
Biomarin
Biosidus
Dong-A Socio Group
ExSAR Corporation
Genzyme
Greencross
Greenovation Biotech
ISU Abxis
JCR Pharmaceuticals
Lixte Biotechnology
Neuraltus Pharmaceuticals
Pharming Group
Protalix
Protalix BioTherapeutics
Shire
UAB Proforma
Neurometabolic Disorders Segment by Type
Pompe Disease
Mucopolysaccharidosis VI
Gaucher’s Disease
Fabry Disease
Other
Neurometabolic Disorders Segment by Application
Oral
Parenteral
Neurometabolic Disorders Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurometabolic Disorders market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neurometabolic Disorders and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurometabolic Disorders.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Neurometabolic Disorders companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Pompe Disease
- Mucopolysaccharidosis VI
- Gaucher’s Disease
- Fabry Disease
- Other
Applications
- Oral
- Parenteral
Companies covered
- Amicus
- Amicus Therapeutics
- Biomarin
- Biosidus
- Dong-A Socio Group
- ExSAR Corporation
- Genzyme
- Greencross
- Greenovation Biotech
- ISU Abxis
- JCR Pharmaceuticals
- Lixte Biotechnology
- Neuraltus Pharmaceuticals
- Pharming Group
- Protalix
- Protalix BioTherapeutics
- Shire
- UAB Proforma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Neurometabolic Disorders by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Pompe Disease
- 2.2.3 Mucopolysaccharidosis VI
- 2.2.4 Gaucher’s Disease
- 2.2.5 Fabry Disease
- 2.2.6 Other
- 2.3 Neurometabolic Disorders by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Oral
- 2.3.3 Parenteral
- 2.4 Assumptions and Limitations
3 Neurometabolic Disorders Breakdown Data by Type
- 3.1 Global Neurometabolic Disorders Historic Market Size by Type (2021-2026)
- 3.2 Global Neurometabolic Disorders Forecasted Market Size by Type (2027-2032)
4 Neurometabolic Disorders Breakdown Data by Application
- 4.1 Global Neurometabolic Disorders Historic Market Size by Application (2021-2026)
- 4.2 Global Neurometabolic Disorders Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Neurometabolic Disorders Market Perspective (2021-2032)
- 5.2 Global Neurometabolic Disorders Growth Trends by Region
- 5.2.1 Global Neurometabolic Disorders Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Neurometabolic Disorders Historic Market Size by Region (2021-2026)
- 5.2.3 Neurometabolic Disorders Forecasted Market Size by Region (2027-2032)
- 5.3 Neurometabolic Disorders Market Dynamics
- 5.3.1 Neurometabolic Disorders Industry Trends
- 5.3.2 Neurometabolic Disorders Market Drivers
- 5.3.3 Neurometabolic Disorders Market Challenges
- 5.3.4 Neurometabolic Disorders Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Neurometabolic Disorders Players by Revenue
- 6.1.1 Global Top Neurometabolic Disorders Players by Revenue (2021-2026)
- 6.1.2 Global Neurometabolic Disorders Revenue Market Share by Players (2021-2026)
- 6.2 Global Neurometabolic Disorders Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Neurometabolic Disorders Head Office and Area Served
- 6.4 Global Neurometabolic Disorders Players, Product Type & Application
- 6.5 Global Neurometabolic Disorders Manufacturers Established Date
- 6.6 Global Neurometabolic Disorders Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Neurometabolic Disorders Market Size (2021-2032)
- 7.2 North America Neurometabolic Disorders Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Neurometabolic Disorders Market Size by Country (2021-2026)
- 7.4 North America Neurometabolic Disorders Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Neurometabolic Disorders Market Size (2021-2032)
- 8.2 Europe Neurometabolic Disorders Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Neurometabolic Disorders Market Size by Country (2021-2026)
- 8.4 Europe Neurometabolic Disorders Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Neurometabolic Disorders Market Size (2021-2032)
- 9.2 Asia-Pacific Neurometabolic Disorders Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Neurometabolic Disorders Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Neurometabolic Disorders Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Neurometabolic Disorders Market Size (2021-2032)
- 10.2 South America Neurometabolic Disorders Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Neurometabolic Disorders Market Size by Country (2021-2026)
- 10.4 South America Neurometabolic Disorders Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Neurometabolic Disorders Market Size (2021-2032)
- 11.2 Middle East & Africa Neurometabolic Disorders Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Neurometabolic Disorders Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Neurometabolic Disorders Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Amicus
- 12.1.1 Amicus Company Information
- 12.1.2 Amicus Business Overview
- 12.1.3 Amicus Revenue in Neurometabolic Disorders Business (2021-2026)
- 12.1.4 Amicus Neurometabolic Disorders Product Portfolio
- 12.1.5 Amicus Recent Developments
- 12.2 Amicus Therapeutics
- 12.2.1 Amicus Therapeutics Company Information
- 12.2.2 Amicus Therapeutics Business Overview
- 12.2.3 Amicus Therapeutics Revenue in Neurometabolic Disorders Business (2021-2026)
- 12.2.4 Amicus Therapeutics Neurometabolic Disorders Product Portfolio
- 12.2.5 Amicus Therapeutics Recent Developments
- 12.3 Biomarin
- 12.3.1 Biomarin Company Information
- 12.3.2 Biomarin Business Overview
- 12.3.3 Biomarin Revenue in Neurometabolic Disorders Business (2021-2026)
- 12.3.4 Biomarin Neurometabolic Disorders Product Portfolio
- 12.3.5 Biomarin Recent Developments
- 12.4 Biosidus
- 12.4.1 Biosidus Company Information
- 12.4.2 Biosidus Business Overview
- 12.4.3 Biosidus Revenue in Neurometabolic Disorders Business (2021-2026)
- 12.4.4 Biosidus Neurometabolic Disorders Product Portfolio
- 12.4.5 Biosidus Recent Developments
- 12.5 Dong-A Socio Group
- 12.5.1 Dong-A Socio Group Company Information
- 12.5.2 Dong-A Socio Group Business Overview
- 12.5.3 Dong-A Socio Group Revenue in Neurometabolic Disorders Business (2021-2026)
- 12.5.4 Dong-A Socio Group Neurometabolic Disorders Product Portfolio
- 12.5.5 Dong-A Socio Group Recent Developments
- 12.6 ExSAR Corporation
- 12.6.1 ExSAR Corporation Company Information
- 12.6.2 ExSAR Corporation Business Overview
- 12.6.3 ExSAR Corporation Revenue in Neurometabolic Disorders Business (2021-2026)
- 12.6.4 ExSAR Corporation Neurometabolic Disorders Product Portfolio
- 12.6.5 ExSAR Corporation Recent Developments
- 12.7 Genzyme
- 12.7.1 Genzyme Company Information
- 12.7.2 Genzyme Business Overview
- 12.7.3 Genzyme Revenue in Neurometabolic Disorders Business (2021-2026)
- 12.7.4 Genzyme Neurometabolic Disorders Product Portfolio
- 12.7.5 Genzyme Recent Developments
- 12.8 Greencross
- 12.8.1 Greencross Company Information
- 12.8.2 Greencross Business Overview
- 12.8.3 Greencross Revenue in Neurometabolic Disorders Business (2021-2026)
- 12.8.4 Greencross Neurometabolic Disorders Product Portfolio
- 12.8.5 Greencross Recent Developments
- 12.9 Greenovation Biotech
- 12.9.1 Greenovation Biotech Company Information
- 12.9.2 Greenovation Biotech Business Overview
- 12.9.3 Greenovation Biotech Revenue in Neurometabolic Disorders Business (2021-2026)
- 12.9.4 Greenovation Biotech Neurometabolic Disorders Product Portfolio
- 12.9.5 Greenovation Biotech Recent Developments
- 12.10 ISU Abxis
- 12.10.1 ISU Abxis Company Information
- 12.10.2 ISU Abxis Business Overview
- 12.10.3 ISU Abxis Revenue in Neurometabolic Disorders Business (2021-2026)
- 12.10.4 ISU Abxis Neurometabolic Disorders Product Portfolio
- 12.10.5 ISU Abxis Recent Developments
- 12.11 JCR Pharmaceuticals
- 12.11.1 JCR Pharmaceuticals Company Information
- 12.11.2 JCR Pharmaceuticals Business Overview
- 12.11.3 JCR Pharmaceuticals Revenue in Neurometabolic Disorders Business (2021-2026)
- 12.11.4 JCR Pharmaceuticals Neurometabolic Disorders Product Portfolio
- 12.11.5 JCR Pharmaceuticals Recent Developments
- 12.12 Lixte Biotechnology
- 12.12.1 Lixte Biotechnology Company Information
- 12.12.2 Lixte Biotechnology Business Overview
- 12.12.3 Lixte Biotechnology Revenue in Neurometabolic Disorders Business (2021-2026)
- 12.12.4 Lixte Biotechnology Neurometabolic Disorders Product Portfolio
- 12.12.5 Lixte Biotechnology Recent Developments
- 12.13 Neuraltus Pharmaceuticals
- 12.13.1 Neuraltus Pharmaceuticals Company Information
- 12.13.2 Neuraltus Pharmaceuticals Business Overview
- 12.13.3 Neuraltus Pharmaceuticals Revenue in Neurometabolic Disorders Business (2021-2026)
- 12.13.4 Neuraltus Pharmaceuticals Neurometabolic Disorders Product Portfolio
- 12.13.5 Neuraltus Pharmaceuticals Recent Developments
- 12.14 Pharming Group
- 12.14.1 Pharming Group Company Information
- 12.14.2 Pharming Group Business Overview
- 12.14.3 Pharming Group Revenue in Neurometabolic Disorders Business (2021-2026)
- 12.14.4 Pharming Group Neurometabolic Disorders Product Portfolio
- 12.14.5 Pharming Group Recent Developments
- 12.15 Protalix
- 12.15.1 Protalix Company Information
- 12.15.2 Protalix Business Overview
- 12.15.3 Protalix Revenue in Neurometabolic Disorders Business (2021-2026)
- 12.15.4 Protalix Neurometabolic Disorders Product Portfolio
- 12.15.5 Protalix Recent Developments
- 12.16 Protalix BioTherapeutics
- 12.16.1 Protalix BioTherapeutics Company Information
- 12.16.2 Protalix BioTherapeutics Business Overview
- 12.16.3 Protalix BioTherapeutics Revenue in Neurometabolic Disorders Business (2021-2026)
- 12.16.4 Protalix BioTherapeutics Neurometabolic Disorders Product Portfolio
- 12.16.5 Protalix BioTherapeutics Recent Developments
- 12.17 Shire
- 12.17.1 Shire Company Information
- 12.17.2 Shire Business Overview
- 12.17.3 Shire Revenue in Neurometabolic Disorders Business (2021-2026)
- 12.17.4 Shire Neurometabolic Disorders Product Portfolio
- 12.17.5 Shire Recent Developments
- 12.18 UAB Proforma
- 12.18.1 UAB Proforma Company Information
- 12.18.2 UAB Proforma Business Overview
- 12.18.3 UAB Proforma Revenue in Neurometabolic Disorders Business (2021-2026)
- 12.18.4 UAB Proforma Neurometabolic Disorders Product Portfolio
- 12.18.5 UAB Proforma Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst